Also any lack of buying interest generally sees sp slip.
It would be a game man or woman to suggest NAl has had its run yet.
With the London listing of immunology, LADS financials making headway in the half yearly's, with US penetration etc...I suggest we have seen this one achieve its potential by a longshot.
